TwoStep Therapeutics
Developing tumor-targeted therapies with broad applicability across solid tumors
Redefining targeted
cancer therapy
Backed by






How TwoStep's targeting molecule works, and where it's headed
Building the future of targeted therapy
Updates from TwoStep
September 2026
Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic
Read article
September 2026
TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate
Read article